Three-Dimensional Quantitative Structure-Activity Relationship Modeling of Cocaine Binding by a Novel Human Monoclonal Antibody

Journal of Medicinal Chemistry

Volumn 47, Issue 1, 2004, Pages 133-142

  Paula, Stefan ^a   Tabet, Michael R ^a   Farr, Carol D ^a,b   Norman, Andrew B ^a   Ball Jr , W James ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b RS Dow Neurobiology Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYLECGONINE; CARBONYL DERIVATIVE; COCAINE; COCAINE DERIVATIVE; ECGONINE; ECGONINE METHYL ESTER; ESTER; HUMAN MONOCLONAL ANTIBODY; METHYL GROUP; NITROGEN; OXYGEN; PHENYL GROUP; PROTON; SOLVENT;

ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPARATIVE STUDY; DRUG BINDING; DRUG SPECIFICITY; ELECTRICITY; ELECTROCHEMISTRY; EXPERIMENT; EXPOSURE; HYDROGEN BOND; HYDROPHOBICITY; METABOLITE; METHODOLOGY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; COCAINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY;

EID: 0346731232     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030351z     Document Type: Article

References (40)

1. NIDA Research Report; NIH Publication Number 99-4342; National Institutes of Health: Bethesda, MD, 1999 (http:// www.nida.nih.gov/PDF/RRCocain.pdf).
2. Carroll, F. I.; Leonard, L. H.; Kuhar, M. J. Pharmacotherapies for Treatment of Cocaine Abuse: Preclinical Aspects. J. Med. Chem. 1999, 42, 2721-2736.
3. De Prada, P.; Winger, G.; Landry, D. W. Application of artificial enzymes to the problem of cocaine. Ann. N. Y. Acad. Sci. 2000, 909, 159-169.
4. Zhan, C.-G.; Zheng, F.; Landry, D. W. Fundamental reaction mechanism for cocaine hydrolysis in human butyryleholinesterase. J. Am. Chem. Soc. 2003, 125, 2462-2474.
5. Tsibulsky, V. L.; Norman, A. B. Satiety threshold: a quantitative model of maintained cocaine self-administration. Brain Res. 1999, 839, 85-93.
6. Norman, A. B.; Norman, M. K.; Hall, J. F.; Tsibulsky, V. L. Priming threshold: a novel quantitative measure of the reinstatement of cocaine self-administration. Brain. Res. 1999, 831, 165-174.
7. Norman, A. B.; Welge, J. A.; Tsibulsky, V. L. Characterization of the distribution of the cocaine priming threshold and the effect of SCH23390. Brain Res. 2002, 946, 253-261.
8. Carrera, M. R.; Ashley, J. A.; Parsons, L. H.; Wirsching, P.; Koob, G. F.; Janda, K. D. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995, 378, 727-730.
9. Carrera, M. R.; Ashley, J. A.; Zhou, B.; Wirsching, P.; Koob, G. F.; Janda, K. D. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6202-6206.
10. Carrera, M. R.; Ashley, J. A.; Wirsching, P.; Koob, G. F.; Janda, K. D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 1988-1992.
11. Fox, B. S.; Kantak, K. M.; Edwards, M. A.; Black, K. M.; Bollinger, B. K.; Botka, A. J.; French, T. L.; Thompson, T. L.; Schad, V. C.; Greenstein, J. L.; Gefter, M. L.; Exley, M. A.; Swain, P. A.; Briner, T. J. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. 1996, 2, 1129-1132.
12. Ettinger, R. H.; Ettinger, W. F.; Harless, W. E. Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol. Biochem. Behav. 1997, 58, 215-220.
13. Kantak, K. M.; Collins, S. L.; Lipman, E. G.; Bond, J.; Giovanoni, K.; Fox, B. S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 2000, 148, 251-262.
14. Abramowicz, D.; Crusiaux, A.; Niaudet, P.; Kreis, H.; Chatenoud, L.; Goldman, M. The IgE humoral response in OKT3-treated patients. Transplantation 1996, 61, 577-581.
15. Hickey, A. R.; Wenger, T. L.; Carpenter, V. P.; Tilson, H. H.; Hlatky, M. A.; Furberg, C. D.; Kirkpatrick, C. H.; Strauss, H. C.; Smith, T. W. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J. Am. Coll. Cardiol. 1991, 17, 590-598.
16. Taylor, L. D.; Carmack, C. E.; Huszar, D.; Higgins, K. M.; Mashayekh, R. ; Sequar, G.; Schramm, S. R.; Kuo, C. C.; O'Donnell, S. L.; Kay, R. M.; Woodhouse, C. S.; Lonberg, N. Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM. Int. Immunol. 1994, 6, 579-591.
17. Lonberg, N.; Taylor, L. D.; Harding, F. A.; Trounstine, M.; Higgins, K. M.; Schramm, S. R.; Kuo, C. C.; Mashayekh, R.; Wymore, K.; McCabe, J. G.; Munoz-O'Regan, D.; O'Donnell, S. L.; Lapachet, S. G.; Bengoechea, T.; Fishwild, D. M.; Carmack, C. E.; Kay, R. M.; Huszar, D. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994, 368, 856-859.
18. Fishwild, D. M.; O'Donnell, S. L.; Bengoechea, T.; Hudson, D. V.; Harding, F.; Bernhard, S. L.; Jones, D.; Kay, R. M.; Higgins, K. M.; Schramm, S. R.; Lonberg, N. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 1996, 14, 845-851.
19. Ball, W. J., Jr.; Kasturi, R.; Dey, P.; Tabet, M.; O'Donnell, S.; Hudson, D.; Fishwild, D. Isolation and characterization of human monoclonal antibodies to digoxin. J. Immunol. 1999, 163, 2291-2298.
20. Larsen, N. A.; Zhou, B.; Heine, A.; Wirsching, P.; Janda, K. D.; Wilson, I. A. Crystal structure of a cocaine-binding antibody. J. Mol. Biol. 2001, 311, 9-15.
21. Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G. Reshaping human antibodies for therapy. Nature 1988, 332, 323-327.
22. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
23. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
24. Green, S. M.; Marshall, G. R. 3D-QSAR: a current perspective. Trends Pharmacol. Sci. 1995, 16, 285-291.
25. Jeffrey, P. D.; Schildbach, J. F.; Chang, C. Y.; Kussie, P. H.; Margolies, M. N.; Sheriff, S. Structure and specificity of the antidigoxin antibody 40-50. J. Mol. Biol. 1995, 248, 344-360.
26. Javaid, J. I.; Fischman, M. W.; Schuster, C. R.; Dekirmenjian, H.; Davis, J. M. Cocaine plasma concentration: relation to physiological and subjective effects in humans. Science 1978, 202, 227-228.
27. Karch, S. B. The Pathology of Drug Abuse; CRC Press: Boca Raton, FL, 1996; Chapter 1.
28. Farr, C. D.; Tabet, M. R.; Ball, W. J., Jr.; Fishwild, D. M.; Wang, X.; Nair, A. C.; Welsh, W. J. Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis. J. Med. Chem. 2002, 45, 3257-3270.
29. The Merck Index, 12th ed.; Budavari, S., Ed.; Merck Research Laboratories: Whitehouse Station, NJ, 1996; pp 2517-2518.
30. Douglas, B. E.; McDaniel, D. H.; Alexander, J. Concepts and Models of Inorganic Chemistry; Wiley: New York, 1994.
31. Paula, S.; Tabet, M. R.; Keenan, S. M.; Welsh, W. J.; Ball, W. J., Jr. Three-Dimensional Structure-Activity Relationship Modeling of Cocaine-Binding to Two Monoclonal Antibodies by Comparative Molecular Field Analysis. J. Mol. Biol. 2003, 325, 516-530.
32. Carroll, F. I.; Kotian, P.; Dehghani, A.; Gray, J. L.; Kuzemko, M. A.; Parham, K. A.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine and 3β-(4′-substituted phenyl)tropane-2β-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J. Med. Chem. 1995, 38, 379-388.
33. Sakurai, M.; Wirsching, P.; Janda, K. D. Design and synthesis of a cocaine-diamide hapten for vaccine development. Tetrahedron Lett. 1996, 37, 5479-5482.
34. +-ATPase. Biochemistry 1998, 37, 6658-6666.
35. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
36. Gabe, E. J.; Barnes, W. H. The crystal and molecular structure of l-cocaine hydrochloride. Acta Crystallogr. 1963, 16, 796-801.
37. Carroll, F. I.; Gao, Y. G.; Rahman, M. A.; Abraham, P.; Parham, K.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Synthesis, ligand binding, QSAR, and CoMFA study of 3β-(p-substituted phenyl)tropane-2β-carboxylic acid methyl esters. J. Med. Chem. 1991, 34, 2719-2725.
38. Newman, A. H.; Izenwasser, S.; Robarge, M. J.; Kline, R. H. CoMFA study of novel phenyl ring-substituted 3α-(diphenylmethoxy)tropane analogues at the dopamine transporter. J. Med. Chem. 1999, 42, 3502-3509.
39. Klebe, G.; Abraham, U. Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bon ding properties and to score combinatorial libraries. J. Comput.-Aided. Mol. Des. 1999, 13, 1-10.
40. Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.